Cancers 2011, 3(2), 2501-2515; doi:10.3390/cancers3022501
Article

Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer

1 Minamata City Hospital and Medical Center, Minamata City, Kumamoto 867, Japan 2 Department of Radiation Oncology, J. Bruce Henriksen Cancer Research Laboratories, University of Nebraska Medical Center, Omaha, NE 68198, USA
* Author to whom correspondence should be addressed.
Received: 4 February 2011; in revised form: 25 April 2011 / Accepted: 17 May 2011 / Published: 25 May 2011
(This article belongs to the Special Issue Pancreatic Cancer)
PDF Full-text Download PDF Full-Text [539 KB, Updated Version, uploaded 31 May 2011 09:12 CEST]
The original version is still available [542 KB, uploaded 25 May 2011 11:44 CEST]
Abstract: Pancreatic cancer does not respond to a single-agent imatinib therapy. Consequently, multimodality treatments are contemplated. Published data indicate that in colorectal cancer, imatinib and radioimmunotherapy synergize to delay tumor growth. In pancreatic cancer, the tumor response is additive. This disparity of outcomes merited further studies because interactions between these modalities depend on the imatinib-induced reduction of the tumor interstitial fluid pressure. The examination of human and murine PDGFr-β/PDGF-B pathways in SW1990 pancreatic cancer xenografts revealed that the human branch is practically dormant in untreated tumors but the insult on the stromal component produces massive responses of human cancer cells. Inhibition of the stromal PDGFr-β with imatinib activates human PDGFr-β/PDGF-B signaling loop, silent in untreated xenografts, via an apparent paracrine rescue pathway. Responses are treatment- and time-dependent. Soon after treatment, levels of human PDGFr-β, compared to untreated tumors, are 3.4×, 12.4×, and 5.7× higher in imatinib-, radioimmunotherapy + imatinib-, and radioimmunotherapy-treated tumors, respectively. A continuous 14-day irradiation of imatinib-treated xenografts reduces levels of PDGFr-β and phosphorylated PDGFr-β by 5.3× and 4×, compared to earlier times. Human PDGF-B is upregulated suggesting that the survival signaling via the autocrine pathway is also triggered after stromal injury. These findings indicate that therapies targeting pancreatic cancer stromal components may have unintended mitogenic effects and that these effects can be reversed when imatinib is used in conjunction with radioimmunotherapy.
Keywords: pancreatic cancer; PDGFr-β; PDGF-B; imatinib; radioimmunotherapy; radiation

Supplementary Files

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Abe, M.; Kortylewicz, Z.P.; Enke, C.A.; Mack, E.; Baranowska-Kortylewicz, J. Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer. Cancers 2011, 3, 2501-2515.

AMA Style

Abe M, Kortylewicz ZP, Enke CA, Mack E, Baranowska-Kortylewicz J. Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer. Cancers. 2011; 3(2):2501-2515.

Chicago/Turabian Style

Abe, Michio; Kortylewicz, Zbigniew P.; Enke, Charles A.; Mack, Elizabeth; Baranowska-Kortylewicz, Janina. 2011. "Activation of PDGFr-β Signaling Pathway after Imatinib and Radioimmunotherapy Treatment in Experimental Pancreatic Cancer." Cancers 3, no. 2: 2501-2515.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert